SLOREL
LIVE

Serial Number

97593502

Owner

CG Bio Co., Ltd.

Attorney

Caroline E. Bryce

Filing Date

Sep 15, 2022

Add to watchlist:

No watchlists yet
View on USPTO

SLOREL Trademark

Serial Number: 97593502 • Registration: 7854495

SLOREL is a trademark filed by CG Bio Co., Ltd. on September 15, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

CG Bio Co., Ltd. (11 trademarks)

3F, 211, Itaewon-ro,

Entity Type: 03

Trademark Details

Filing Date

September 15, 2022

Registration Date

July 8, 2025

Published for Opposition

May 20, 2025

Goods & Services

Surgical implants comprised of living tissues for guided tissue regeneration; implants comprising living tissue; implantable materials for use in guided tissue regeneration in the nature of implants comprising living tissue; Surgical implants comprised of living tissues used in transplants, namely, vascular grafts being living tissue and human allograft tissue; surgical implants comprised of living tissues; human allograft tissue; bone void fillers comprised of living tissues; Stem cells for medical purposes, namely, surgical implants grown from stem cells; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for tissue regeneration; medicines for human purposes, namely, pharmaceutical preparations for the treatment of musculo-skeletal disorders; medicines for human purposes, namely, a drug delivery system comprising liquids, powders, tablets or capsules for the continuous release of a wide variety of therapeutic agents, namely, pharmaceutical preparations for the treatment of musculo-skeletal disorders; drugs for medical purposes, namely, drugs for use in bioregenerative procedures, drugs for use for regenerative purpose, drugs for use to assist with artificial bone growth, drugs for use in accelerating bone formation, drugs for use to stimulate new bone formation; pharmaceutical agents affecting sensory organs; pharmaceutical preparations for the prevention of diseases of the musculo- skeletal system; pharmaceutical preparations for the treatment of Musculo-skeletal disorders; cellular function activating agents for medical purposes; pharmaceutical preparations for use in organ transplantation; biological tissue cultures for medical purposes; drug delivery agents in the form of liquid, powders, tablets and capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films added to bone substitutes that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films for use in bioregenerative procedures that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that provide sustained release of drugs for use with implants and bone substitutes that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films with controlled timing and rate of drug release that facilitate the delivery of pharmaceutical preparations; medicines for human use, namely pharmaceutical preparations for the treatment of musculo-skeletal disorders featuring controlled timing and rate of release; medical bone graft substitute, namely, biological tissue bone grafts; medical bone graft materials, namely, bone fillers consisting of living materials; medical bone graft materials with drug release function being bone growth media consisting of biological materials for medical bone graft purposes with drug release function; medical bone graft materials, namely, biological bone tissue intended for subsequent implantation in a bone graft with drug release function, that provide sustained release of drugs for use with implants and bone substitutes; medical bone graft materials being biological bone tissue intended for subsequent implantation with drug release function that are sold filled with pharmaceutical preparations, namely, biological growth factors, used with implants and bone substitutes; medical bone graft materials being biological bone tissue intended for subsequent implantation with drug release function that are sold filled with pharmaceutical preparations, namely, antibiotics, used with implants and bone substitutes

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 8, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 8, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 20, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 20, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 14, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 17, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 14, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 14, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 8, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jan 8, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jan 8, 2025 CNRT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 17, 2024 CHAN
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Dec 12, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 12, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 12, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 12, 2024 REAP
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 12, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 12, 2024 CRFA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Nov 6, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 6, 2024 TCCA
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Nov 6, 2024 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 6, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 6, 2024 REAP
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 6, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 6, 2024 CRFA
ASSIGNED TO LIE
Nov 5, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Aug 13, 2024 ERSI
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 12, 2024 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jan 17, 2024 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 16, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 16, 2023 GNSL
SUSPENSION LETTER WRITTEN
Jun 16, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 12, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 12, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 12, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 14, 2023 GNRN
NON-FINAL ACTION E-MAILED
Apr 14, 2023 GNRT
NON-FINAL ACTION WRITTEN
Apr 14, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 14, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 1, 2022 NWOS
NEW APPLICATION ENTERED
Sep 19, 2022 NWAP